Abstract
In The Lancet Haematology, Catherine Diefenbach and colleagues1 report results of a phase 1b/2 study evaluating the CD79b-directed antibody–drug conjugate polatuzumab vedotin in combination with the anti-CD20 antibody obinutuzumab and the immunomodulatory drug lenalidomide in a cohort of patients with relapsed or refractory follicular lymphoma.1
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
